Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (April 2024)
15 slides from Microbot Medical's investor presentation, Apr 24, 2024
Slide 1: Microbot: Access-Ability for All
microbot ACCESS-ABILITY FOR ALL”
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation (together with any oral statements made in connection herewith, the “Presentation”), is provided for informational purposes only and has been prepared to assist interested parties in evaluating Microbot Medical Inc. (“Microbot”) and for no other purpose. T
Slide 3: Surgical Robotics Today
Slide 4: Procedures
oM+ PROCEDURES'
Slide 5: Supported by Interventionalists
SUPPORTED BY INTERVENTIONALISTS Do you anticipate that you will begin using a robotic-assisted vascular intervention system in the future? Ne) YES | do not expect Within to personally use them year YES YES in 3+ years Within >1-3 years 'N=200 inlerventionaliss, data on fle
Slide 6: Less Than 1% Done Robotically
LESS THAN 1% DONE ROBOTICALLY'
Slide 7: Multiple Barriers Leading to Low Penetration
MULTIPLE BARRIERS LEADING TO LOW PENETRATION Ye e) Special training, i} long learning curve Extended Large set-up time footprint ——_— —— | — a Dedicated expense infrastructure Cumbersome and expensive disposables
Slide 8: Eliminating Barriers, Allowing Access
ELIMINATING BARRIERS, ALLOWING ACCESS
Slide 9: Eliminating Barriers, Allowing Access
ELIMINATING BARRIERS, ALLOWING ACCESS Disposable Remote + No capital expense + Reduce exposure to radiation* * Increases procedure * Eliminate user physical strain* efficiency + Telesurgery enabled Universal * Compatible with off-the- shelf instruments Small Footprint * Compact & Light + No dedicate
Slide 10: Access-Ability for All
ACCESS-ABILITY FOR ALL™
Slide 11: LIBERTY Product Lifecycle (Current)
LIBERTY PRODUCT LIFECYCLE (CURRENT) LIBERTY Open System * Compatible with all OEM devices * Initial focus on peripheral vascular procedures Expand to include neuro-vascular and coronary applications
Slide 12: Initial Target Therapies
INITIAL TARGET THERAPIES Liver Gl (metastasis) (Rema, hemorrhoids) * Embolotherapy (Peripheral Vascular) + Interventional Oncolo: Vascular ; is malformation Kidney + MSK (metastasis) + Others Prostate Uterine (BPH) (fibroids) Msk
Slide 13: Regulatory Status
REGULATORY STATUS CERTIFIED
Slide 14: LIBERTY Product Lifecycle: LIBERTY+
LIBERTY PRODUCT LIFECYCLE* LIBERTY+™ Remote Enabled = SGIMIFi enabled * Integration into multiple site/satellite locations = Enable remote procedures, proctoring, training *Under evaluation [internally & via clinical partner)
Slide 15: LIBERTY Product Lifecycle: LIBERTY MAX
LIBERTY PRODUCT LIFECYCLE** LIBERTY MAX™ Autonomous Procedures = Plan, Monitor, Insert, Steer = Compatibility with CBCT with 3D imaging = Compatibility with Navigation system = AVML Inte **Potential long-term future offering
Microbot Medical — Investor Presentation (April 2024) on 6ix